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lower blood pressure and serum Na and were more likely to have had a recent HF hospi- 
talization (all P < 0.001). Results. Shown below are 1-year Kaplan-Meier ates and Cox 
model hazard ratios (CRV:PBO): 
Spironolactone No Spironolactone 
PBO CRV Hazard PBO(n=908) CRV (n=936) Hazard ratio 
(n=225) (n=220) ratio 
All-cause 19.1% 11.4% 0.65 18.4% 11.3% 0.65 
mortality 
Death or 39.3% 26.3% 0.63 37.5% 25.4% 0.70 
hospitalization 
for worsening HF 
Death or 41.6% 29.1% 0.61 41.6% 30.4% 0.75 
cardiovascular 
hospitalization 
Death or any 47.2% 38.4% 0.76 53.3% 42.1% 0.76 
hospitalization 
CRV reduced the risk of a major clinical event in patients on spironolactone to an extent 
similar to that seen in patients not on spironolactone. 
Conclusion. These data indicate that the morbidity and mortality of patients with severe 
HF receiving drugs that interfere with more than one neurohormonal target can be 
reduced substantially with further neurohormonal antagonism (with CRV). 
1157-160 Beta-Blocker Utilization in Heart Failure Patlenta: 
Experience From a Heart Failure Clinic 
Ritash Gueta, W.H. Wilson Tang, James B. Young, Cleveland Clinic Foundation, 
Cleveland, Ohio. 
Background: Beta blockers (BB) reduce mortality in heart failure (HF) patients. Though, 
well tolerated in clinical trials, utilization rates in clinical settings have not been studied. 
Methods: Retrospective analysis of 500 consecutive HF patients presenting to a HF 
clinic between 3/01 to 5/01 (mean age 61, 69% males, 53% ischemic, mean LVEF 27%). 
Chi-square test was utilized for subgroup analysis. 
Results: 75% of patients had been given a BB trial and 69% were currently on BB. The 
use of BB was more in moderate (LVEF 20 - 40, n=236) compared to mild (LVEF >40, n 
= 92) and severe (LVEF <20, n =141) HF (73% vs. 60% and 65%, p=0.04). BB use also 
decreased with worsening NYHA class of HF symptoms (I 76%, II 72%, III & IV 60%, 
p=0.01). No difference in BB use by gender was seen (68% in males vs. 71%, p=0.5). 
Discontinuation rate was 6.8% and was not influenced by NYHA class (p=0.3). Down 
titration was required in 5.2%. Side effects leading to stopping or down titration, included 
dizziness (3.2%), fatigue (2.8%), hypotension (2.6%), bradycardia (2.0%), and others 
(1.4%). A contraindication could be identified in 44% of patients never tried on BB with 
respiratory disease being the most common in 33%, uncompensated state in 7%, A-V 
block in 1% and hypotansion in 1.6%. Subgroup of diabetics had lower BB use than non 
diabetics(60% vs 73%, p=0.02) with more contraindications (36% vs. 18%, p < 0.01 ) and 
worse NYHA class (p= 0.03) though LVEF was similar (p=0.5). Trend towards lower BB 
use was seen in elderly patients (age >74) than younger patients (61% vs. 71%, p=0.06) 
but there was no difference in rate of contraindication to BB(29% vs. 23%, p= 0.1 ). 
Conclusion: High utilization rates for BB (69% current usage) can be achieved with an 
aggressive approach to initiating BB therapy. Respiratory diseases are the most common 
reason of not initiating BB therapy. Diabetics and elderly patients are less likely to be on 
BB. Diabetics tend to have more contraindications to BB and worse NYHA class than 
non diabetics, which may explain lower use of BB in them. Eldedy patients do not show 
this trend and lower use in this group needs further investigation. 
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1158-146 Phosphoramidan Ameliorates the Functional Sequelae 
of Experimental  Chronic Chagasic Cardiomyopathy 
Madhulika Chandre, Herbert B. Tanowitz. Vitally Shtufln, Jamshid Shirani, Albert Einstein 
College of Medicine, Bronx, New York. 
Background. Trypanosoma crozi, the etiologic agent of Chagas' disease, is an important 
cause of chronic cardiomyopathy. Coronary microvascular spasm, in part mediated by 
endothelin-1, appears to play a significant role in the pathogensis of experimental chronic 
chagasic cardiomyopathy. Aim. We sought to assess if the administration of an endothe- 
lin inhibitor, phosphoramidan, could influence the severity of cardiomyopathy in mice 
infected with T. cruzL Methods. Therefore we infected cdl mice (n=21) with 104 trype- 
mastigotes of the Brazil strain of "K cruzi. Of these, 8 were treated with phosphoramidan. 
An additional 8 uninfected littermatas ewed as controls (C), 3 of which received phos- 
phorarnidan. All mice (n--29) survived and were evaluated at 150 days post infection by 
transthoracic echocardiography. Left ventricular (LV) end diastolic diameter (EDD), rela- 
tive wall thickness (RW'F), and fractional shortening (FS) were measured. Right ventricu- 
lar (RV) size was assessed semi-quantitatively on a scale of 0-3. Results. There was no 
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effect of phosphoramidan on LV EDD, RWT, FS or RV in uninfected (C) mice. Infected, 
untreated mica (INF) had increased LV EDD (3.2±0.1 v 2.8±0.1mm, p<0.05), along with 
reduced FS (39±2 v 57±1%, p<0.05) and RWT (0.4±0.0 v 0.5±0.0, p<0.05), compared 
with C. Treatment with phosphoramidan reduced the magnitude of these changes, such 
that the infected, phcaphoramidan treated mica (INF+P) had no significant differences in 
LV EDD (2.9±0.1 v 2.8±0.1mm), RWT (0.5±0.1 v 0.5±0.1), and FS (57±2 v 50¢4%) com- 
pared with C mice. Similarly, RV was larger in INF compared with both C and INF+P mice 
(2.1¢0.3 ,) 1.5±0.4, INF v INF+P respectively, p<0.01). Conclusion. These data indicate 
that phosphoramidan ameliorates the functional sedulae of experimental chronic cha- 
gasic cardiomyopathy. 
1158-147 Molecular Epidemiology of Cardiac Actin Gene 
Mutations in Dilated Cardlomyopathy 
Ronald Zoltv, G. Passarino, M. R. Taylor, A. Moss, L. Mastroni, M. R. Bristow, UCHSC, 
Denver, Colorado, Stanford University, Palo Alto, California. 
Background: Dilated cardiomyopathies (DCM) are characterized by a large vantricular 
dilatation and impaired systolic function. There is a strong genetic component in DCM, 
estimated to be present in approximately 20-30percent of cases. Mutations in axons 5 
(Arg312His) and 6 (Glu361Gly) of cardiac actin gene (ACTC) have been reported in two 
families with DCM. Methods: In order to evaluate prevalence and characteristics of 
ACTC gene mutations in DCM, 62 patients from different ethnic backgrounds were stud- 
ied: 17 with sporadic DCM, 45 with familial DCM (belonging to 31 unrelated families). 
Two patients with ischemic heart disease were used as controls. Genomic DNA was 
extracted from blood or explanted heart tissue using standard procedures. PCR products 
were generated from all 6 exons of the ACTC gene, allowing the inclusion of the exon,' 
intron boundaries. Mutation analysis of all 6 axons was performed using denaturing high 
performance liquid chromatography (DHPLC) and sequence analysis. Results: No muta- 
tion was found in any of the six ACTC exons. A single nuclectide pelymorphism was 
detected by DHPLC, and confirmed by sequence analysis in intron 5 (C-62T). Conclu- 
sions: ACTC mutations do not seem to be associated with DCM in our large population of 
familial and sporadic DCM. ACTC mutations appear to be infrequently associated with 
DCM 
1158-148 Noninvseive Asselmment of Coronary Flow Reserve 
Impairment in Patients With Systemic Sclerosis 
Roberta Montisci. Paolo Colonna, Massimo Ruscazio, UJun Chen, Carlo Caiati, Pietro 
Gareu, Giuseppe Passiu, Alassandra Vacca, Alessandro Mathieu, Sablno Ilicato, 
Department of Cardiovascular and NeuroL Sciences, Cagliari, italy, Institute of 
Rheumathology, Cagliari, Italy. 
Background. Systemic sclerosis (SSc) is a chronic connective tissue disorder of 
unknown etiology, characterized by cutaneous and visceral tissue fibrosis with arteitolar 
and capillary ischemic dysfunction. The pathogenesis of the cardiac lesion in SSc is con- 
troversial, but the primary disorder of microvasculature with diffuse artsriolar and capil- 
lary lesions could precede any fibrosis, thus causing ischemic disorder to the head. CFR 
is used to evaluate coronary microcirculation, and has been already employed to investi- 
gate myocardial microcirculation impairment in SSc. Previous invasive studies have 
demonstrated that coronary flow reserve (CFR) is impaired in patients (pts) with 
advanced SS and cardiac involvement. We tested the hypothesis that CFR can be early 
impaired in patients with systemic sclerosis without cardiac involvement and whether 
CFR impairment is correlated to the cutaneous subset. 
Methods. We studied 26 patients with SSc without clinical evidence of heart disease, (14 
with diffuse form and 12 with localized form of SSc) and 22 control group patients, 
matched in age and gender. We evaluated CFR in the left anterior descending coronary 
artery (LAD) with a new non-invasive method : contrast (Levovist) enhanced transtho- 
racic Doppler (CEE-TTE) during adenosine infusion. The pulsed wave Doppler of blood 
flow velocity was recorded in the LAD at rest and after maximum vasodilaflon by adenos- 
ine infusion (140 mcg/Kg/min in 5 minutes). 
Results: In patients with SSc, without clinical evidence of heart disease, CFR was 
impaired (2.65:t:0.63 vs 3.29~0.52 in controls, p < 0.0005). A significantly, greater per- 
centage of SSc patients had reduction of (_< 2.5) CFR compared to controls ( 48% vs 
4.5%, p=0.003). Left ventricular mass and ejection fraction were not statistically different 
in the two groups. A non-significant trend between mean CFR and the severity and dura- 
tion of the disease was also observed. 
Conclusion. in this cross-sectional study we demonstrated that CFR is early reduced in 
patients with SSc and seems to be correlated to the extension of the cutaneous subset of 
the disease. A reduction of CFR could be an early sign of cardiac involvement in sys- 
temic sclerosis. 
1158-149 Clinical Course of Dilated Cardiomyopathy in 
Asymptomatic Patients Long-Term Treated With Beta- 
Blocking Agents: The Heart Muscle Disease Registry of 
Trieste 
Andrea Di Lenarda, Gastone Sabbadini, Gererdina Lardieri, Mauro Driussi, Elisa Camiel, 
Laura Vitali Serdoz, Stafano Pangher, Gianfranco Sinagra, Department of Cardiology, 
Trieste, Italy, Department of Medicine and Geriatrics, Trieste, Italy. 
No conclusive data are available on long-term effects of adding a beta-blocker (BB) to 
ACE-inhibitor (ACE-I) therapy in asymptomatic patients with dilated cardiomyopathy 
(DC). 
Among 447 DC patients consecutively enlisted in the Heart Muscle Disease Registry of 
Trieste between 1986 and 2000, 307 (68.7%) had HF symptoms (NYHA II-IV, Group 1) 
while 140 (31.3%) were asymptomatic (NYHA I, Group 2) at enrolmect, in Group 2, a 
previous history of HF was present in 71 patients (50.7%)(Group 2a) and absent in 69 
(49.3%)(Group 2b). 
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As compared to patients of Group 1, those of Group 2 were younger (47±14 vs 41±15 
years, p<0.001), and showed less advanced LV dysfunction (EF 28±9 vs 35±9%, 
p<0.001) and remodelling (end-diastolic diameter index 38±7 vs 35±7 minim2, p<0.001) 
at the time of diagnosis. Most patients of Group 1 and 2 were treated with ACE-I (93% 
and 88%, p=NS) and BB (83% and 74%, p<0.05). 
Five and 10-year transplant-free survival was respectively 73 and 57% in Group1 vs 93 
and 86% in Group 2, while hospitatisation-free survival was 47 and 32% in Group1 vs 70 
and 57% in Group 2 (both p<0.001). No outcome difference was observed between 
Group 2a and 2b, whereas 5 and 10-year transplant-free survival was significantly better 
in patients of Group 2 who were treated with BB than in those not receiving BB (p=0.007 
after stratification for the severity of the disease). 
At 6 to 8 years of follow-up, 38% of patients of Group 2 developed HF symptoms, and/or 
a decrease of LVEF>10%, and/or the need of hospitalisation for cardiovascular reasons. 
The long-term progression of HF symptoms and LV dysfunction was similar in asymp- 
tomatic patients of Group 2a and 2b and not significantly different to that of patients of 
Group 1. 
Even though asymptomatic DC patients receiving an optimal medical treatment are char- 
acterized by low rates of death or heart transplant, nevertheless during a long-term fol- 
low-up they frequently exhibit a worsening of clinical status and LV function. Our data 
suggest that in these patients an early and aggressive BB strategy should be carefully 
considered in order to counteract as much as possible the Ioeg-term progression of the 
disease. 
1158-150 Functional Significance of Myocyte Endothelin-1 in 
Experimental Chronic Chagasic Cardiomyopathy 
Madhuiika Chandra. Herbert B, Tanowitz, Yaz Y. Kisanuki, Masashi Yanagisawa, 
Jamshid Shirani, Albert Einstein College of Medicine, Bronx, New York. 
Background. Trypanosorna cruzi, the etiologic agent of Chagas' disease, is an important 
cause of chronic cardiomyopathy. Endothelin-1 (ET-1) has been implicated in the patho- 
genesis of chronic chagasic heart disease, possibly due to its effect on the coronary 
microvasculature. Aim and Methods, In order to assess the role of ET-1 in the patho- 
genesis of chronic chagasic cardiomyopathy, we infected ET-1 (flox/flox); (x-MHC-Cre (+) 
(ETKO) mice, in which the ET-1 gene has been deleted from cardiac myocytes, with 104 
trypomastigotes of T. cruzi (Brazil strain). We also infected ET-1 (flox/flox); Cre (-) (FLOX) 
mice. Uninfected littermates of both groups served as controls. All mice (n=28) survived 
and were evaluated at 160-170 days post infection by transthoracic echcoardiography. 
Left ventricular (LV) end diastolic diameter (EDD), relative wall thickness (RWT), and 
fractional shortening (FS) were measured. Right ventricular (RV) size was assessed 
semi-quantitatively on a scale of 0-3. Results. Compared with their respective, unin- 
fected controls, both infected ETKO and FLOX mice had increased LV EDD[(3.8±0.3 v 
2.7±0.1mm, FLOX), and (3.0±0.1 v 2.6±0.1mm, ETKO), both p<0.05], along with 
reduced LV FS[(40±3 v 53±1%, FLOX) and (47±2 v 56±2%, ETKO), both p<0.05] and 
RWT[(0.4±0.0 v 0.5±0.0, FLOX) and (0.5±0.0 v 0.6±0.0 ETKO), both p<0.05]. However 
the magnitude of these changes was attenuated in the infected ETKO group as com- 
pared with the infected FLOX group (p<0.05 for LV EDD, RWT, and FS). Similarly, RV 
was larger in infected FLOX compared with ETKO (2.5±0.3 v 0.6±0.3, respectively, 
p<0.01). Conclusions. These data provide support for the role of ET-1 in pathogenesis 
and progression of chronic chagasic heart disease and indicate that the cardiac myocyte 
is an important source of ET-1 in this disease. 
1158-151 Mitochondrial Respiratory Abnormalities in Ventricular 
Myocardium of Patients With End-stage Congenital 
Heart Disease 
Seema Mital, Alessandro Barbone, Ralph J. Mosca, Jan M. Quaegebeur, Linda J. 
Addonizio, Thomas H. Hintze, Columbia University, New York, New York. 
Background: Nitric oxide (NO) binds to mitochondrial cytochrome oxidase to decrease 
myocardial oxygen consumption (MVO2). This regulation is disrupted in end-stage heart 
failure in part due to reduced'NO availability. We compared NO mediated regulation of 
MVO2 in patients with end-stage congenital heart disease (CHD) vs cardiomyopathy 
(CMP) undergoing cardiac transplantation. 
Methods: MVO2 was measured in vitro using a Clark type oxygen electrode in LV muscle 
segments obtained from explanted failing human hearts at heart transplantation. This 
included 7 Lots with complex CHD (mean age 11±10 years) and 14 pts with dilated CMP 
(mean age 25±26 years). We measured the effect of increasing doses (10-7-10-4M) of 
the following NO agonists on MVO2 - amlodipine, ramiprilat, bradykinin - all of which 
cause kinin-dependent NO production, and exogenous NO donors, S-nitroso N-acetyl 
penicillamine (SNAP) and nitroglycerin (NTG). MVO2 was measured with and without 
addition of nitro-L-arginine methyl ester (L-NAME, 10-4 M), NO synthass inhibitor. 
Results: All drugs caused a significant dose-dependent decrease in MVO2 in both 
groups. However, myocardium from CHD pts showed a smaller decrease in MVO2 in 
response to NO agonists compared to CMP pts. Changes in MVO2 at highest dose in 
C;HD vs CMP respectively are shown - amlodipine, -5±7% vs -29±6%, p<O.O01; ramipri- 
lat, -17±8% vs -26±2%, p=O.05; and bradykinin, -22±7% vs -30±5%. NO donors, SNAP 
and NTG also caused smaller decreases in MVO2 in CHD vs CMP (SNAP, -37±4% vs - 
49±3% and NTG, -16±6% vs -37±4% raspectively)(p<0.01). Therefore, NO donors were 
unable to completely reverse altered regulation of MVO2 in CHD suggesting abnormal 
mitochondrial function. L-NAME, NO inhibitor, attenuated the effect of amlodipine, ramip- 
rilat and bradykinin but not of SNAP and NTG. 
Conclusion: Abnormal regulation of MVO2 in end-stage heart failure may be secondary 
to reduced NO availability and can be reversed by use of NO agonists. In end-stage 
CHD, however, this abnormality may be related at least in part to abnormal mitochonddal 
function. 
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1158-152 Improved Glycemic Control Induces Regression of Left 
Ventricular Mass in Patients With Type 1 Diabetes 
Mellitus 
Fr~,nz C. Aeofelbacher. Susan B. Yeon, Larry A. Weinrauch, John D'Elia, Andrew J. 
Burger, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Joslin Diabetes 
Center, Boston, Massachusetts. 
Background: Diabetes mellitus has been associated with abnormalities of cardiac func- 
tion and left ventrioular hypertrophy. However, the effect of improved glycomic control on 
these parameters is controversial and may be confounded by the type of glycemic ther- 
apy or alterations in blood pressure levels. 
Methods: We studied 19 patients (mean age 40 ± 9 years) with longstanding type I dia- 
betes mellitus (28 ± 4 years), who participated in a program of stringent glycomic control 
using insulin injections. Glycemic control was monitored with hemoglobin Alc (Hb Alc) 
levels; improvement was defined as > 1% (absolute) decrease of Hb Alc. Two-dimen- 
sional and Doppler echocardiegrams and 24-hour ambulatory blood pressures (24h 
ABP) were obtained at baseline and after 1 year. Left ventricular (LV) mass was deter- 
mined using the area-length method. 
Results: Hb Alc and echocardiographic data (mean + SD) are shown below. Septal 
thickness decreased for all patients; septal thickness and LV mass regressed for the sub- 
group with improved glycemic control. Left ventricular function and 24h ABP parameters 
remained unchanged after 1 year in both groups. 
Conclusions: Improved glycemic control induces regression of septal thickness and LV 
mass without significant effect on systolic or diastolic function, importantly, these 
changes occurred in the absence of significant alterations in 24h ABP levels. 
All Patients (n=19) Patients with improved 
glycemic control (n=12) 
Baseline 1 Year Baseline 1 Year 
Hemoglobin Alc (%) 9.5 ± 1.6 8.2 ± 1.5" 9.8 ± 1.5 7.8 ± 1.2" 
LV mass (gm) 203 ± 53 185 ± 59 205 ± 35 182 ± 46"i" 
LV septum (mm) 10.3 ± 1.3 9.7 ± 1.6t 10.3 ± 1.4 9.4 ± 1.7"i" 
LV posterior wall (mm) 9.9 ± 1.4 9.6 ± t .1 9.9 ± 1.3 9.6 ± 0.9 
LV diastolic diameter (ram) 46 ± 5.8 46.9 ± 5.7 45.3 ± 4.1 46.3 ± 4.1 
LV systolic diameter (mm) 28.2 ± 4.2 28.3 ± 5.8 27.4 ± 3.6 27.7 ± 4.9 
Fractional shortening (%) 38.7 ± 5.3 40.2 ± 6.9 39.5 ± 5.7 40.5 ± 6.9 
E/A ratio of mitral inflow 1.23 ± 0.4 1.29 ± 0.5 1.25 ± 0.4 1.33 ± 0.5 
E-wave deceleration time (ms) 191 ± 40 188 ± 37 176 ± 33 190 ± 40 
*p<O.O01 vs baseline, tp<0.05 vs baseline 
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1159-137 Impact  of  Percutaneous Coronary Intervention on 
Functional Status: Results from the ADORE Trial 
Sabdna Cuono. Mark J. Eisenberg, James Blankenship, Thao Huynh, Michael Azrin, 
Steven Sedlis, Louise Pilote, Jewish Genera/Hospital Montreal Quebec, Canada. 
Background: 
While it is well known that percutaneous coronary intervention (PCI) is effective at reduc- 
ing angina and other markers of coronary artery disease (CAD), little is known about the 
magnitude of functional status and angina class improvement as well as the magnitude 
of anti-anginal drug use after PCI in the general post-PCI patient population. 
Method: 
To determine the magnitude to which PCI effects functional status, angina ctass and anti- 
anginal drug use, 9-month post-PCI results were compared with results obtained 3- 
months prior to PCI in 109 patients. Patients were enrolled in the Aggressive Diagnosis 
Of Restenosis (ADORE) Trial, a randomized clinical trial which examined functional test- 
ing in patients who underwent complete coronary revasculadzation by a percutaneous 
technique, 
Results: 
A significant improvement in functional status, measured by an increase in METS, was 
observed 9-months after PCI when compared to 3-months prior (9.7 vs 7.4, p<0.0001). In 
addition, a significant difference was found between 9-month post-PCI functional test 
results and those obtained 3-months prior: reversible ischamia detected by ECG (19.4 vs 
63.0, p< 0.0001 ), clinically determined reversible ischemia (10.2 vs 58.6, p<0.0001 ), and 
electrically or clinically positive functional test result (23.4 vs 83.7, p<0.0001). A signifi- 
cant improvement in CCS angina class was also found post-PCI (CCS class 1 or 2:24.5 
vs 43.5, p=0.001, and CCS class 3 or 4:1.0 vs 46.3, p<0.0001). A marked decrease in 
anti-anginal drug use was further noted after PCI (16.0 vs 30.6, p=0.0001). 
Conclusions: 
Complete revasculanzation with PCI leads to substantiat improvements in functional sta- 
tus and CCS angina class, and is associated with decreased use of anti-anginal 
drugs.Thus, this procedure is beneficial in patients with CAD. 
